NZP NEWS

Patients with HIBM

The U.S. National Institutes of Health Clinical Center (NIH CC) in Bethesda, Maryland, U.S. is running a natural history study on patients with hereditary inclusion body myopathy (HIBM).  This study is a pre-requisite for patients who wish to participate in clinical trials that will eventually determine the safety and efficacy of the active pharmaceutical ingredient, DEX-M74, manufactured by New Zealand Pharmaceuticals Ltd.

 This study is not a pre-requisite for patients who wish to participate in clinical trials that will eventually determine the safety and efficacy of the active pharmaceutical ingredient, DEX-M74, manufactured by New Zealand Pharmaceuticals Ltd. However, Natural History studies are an essential part of developing a new and effective drug and we encourage people connected with HIBM to contact Dr Nuria Carrillo at the NIH CC about more information.